Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

AI software as a third reader in breast cancer screening—a prospective diagnostic observational study

View through CrossRef
Abstract Objective Despite advances in mammography screening, some cancers remain undetected, prompting the evaluation of artificial intelligence (AI) as an independent third reader to reduce missed cancers. Materials and methods In this prospective study, women eligible for the German Mammography Screening were enrolled at six sites belonging to one screening unit between August 2023 and February 2024. Each mammogram underwent double reading and was independently analyzed using Transpara, an AI-based detection software. Cases rated BI-RADS 4 or 5 by any reader or given a risk score of 10 by the software were reviewed in a consensus conference. Endpoints included: primary—cancer detection rate (CDR) and positive predictive values (PPV); secondary—analysis of cancers detected only by the software or missed by it. Results 15,356 female participants (mean age 58.6 ± 5.6 years) were included. Overall, 115 breast cancers were detected (CDR triple reading: 0.75%; 95% CI: 0.62%, 0.90%). CDR of double reading and standalone AI was 0.68% (95% CI: 0.56, 0.83%) and 0.66% (95% CI: 0.54, 0.81%). Using Transpara as a third reader increased the detection rate by 9.5% (95% CI: 4.7%, 16.8%) compared to double reading ( p  = 0.002). The PPV for consensus-conference referrals was 5.1% (95% CI: 4.2%, 6.1%), lower than double reading 7.5%(95% CI: 6.2%, 9.0%; p  < 0.001). For recalled cases, the PPV was 13.7%(95% CI: 11.5%, 16.2%) versus 15.2% (95% CI: 12.6%, 18.1%; p  < 0.001). All nine invasive cancers detected solely by AI were Luminal-A-like cancers. Among 13 cancers missed by the software, four were triple-negative. Conclusion Adding Transpara as an independent third reader improved detection rates, mainly by identifying additional Luminal-A-like cancers, and increased the workload to the consensus conference and the number of recalled cases. Key Points Question Does the integration of AI software as an independent third reader improve cancer detection rates in mammography screening without increasing false-positive findings and recall rates? Findings AI as an independent third reader increased cancer detection by 9.5%, mainly identifying Luminal-A-like cancers, significantly decreasing the positive predictive values of cases referred to at the consensus conference and increasing the number of recalled cases. Clinical relevance Using AI as an independent third reader enhances mammographic cancer detection by offering radiologists complementary sensitivity, especially for low-risk lesions. However, maintaining human readers is essential, as AI may miss aggressive subtypes like triple-negative breast cancers. Graphical Abstract
Title: AI software as a third reader in breast cancer screening—a prospective diagnostic observational study
Description:
Abstract Objective Despite advances in mammography screening, some cancers remain undetected, prompting the evaluation of artificial intelligence (AI) as an independent third reader to reduce missed cancers.
Materials and methods In this prospective study, women eligible for the German Mammography Screening were enrolled at six sites belonging to one screening unit between August 2023 and February 2024.
Each mammogram underwent double reading and was independently analyzed using Transpara, an AI-based detection software.
Cases rated BI-RADS 4 or 5 by any reader or given a risk score of 10 by the software were reviewed in a consensus conference.
Endpoints included: primary—cancer detection rate (CDR) and positive predictive values (PPV); secondary—analysis of cancers detected only by the software or missed by it.
Results 15,356 female participants (mean age 58.
6 ± 5.
6 years) were included.
Overall, 115 breast cancers were detected (CDR triple reading: 0.
75%; 95% CI: 0.
62%, 0.
90%).
CDR of double reading and standalone AI was 0.
68% (95% CI: 0.
56, 0.
83%) and 0.
66% (95% CI: 0.
54, 0.
81%).
Using Transpara as a third reader increased the detection rate by 9.
5% (95% CI: 4.
7%, 16.
8%) compared to double reading ( p  = 0.
002).
The PPV for consensus-conference referrals was 5.
1% (95% CI: 4.
2%, 6.
1%), lower than double reading 7.
5%(95% CI: 6.
2%, 9.
0%; p  < 0.
001).
For recalled cases, the PPV was 13.
7%(95% CI: 11.
5%, 16.
2%) versus 15.
2% (95% CI: 12.
6%, 18.
1%; p  < 0.
001).
All nine invasive cancers detected solely by AI were Luminal-A-like cancers.
Among 13 cancers missed by the software, four were triple-negative.
Conclusion Adding Transpara as an independent third reader improved detection rates, mainly by identifying additional Luminal-A-like cancers, and increased the workload to the consensus conference and the number of recalled cases.
Key Points Question Does the integration of AI software as an independent third reader improve cancer detection rates in mammography screening without increasing false-positive findings and recall rates? Findings AI as an independent third reader increased cancer detection by 9.
5%, mainly identifying Luminal-A-like cancers, significantly decreasing the positive predictive values of cases referred to at the consensus conference and increasing the number of recalled cases.
Clinical relevance Using AI as an independent third reader enhances mammographic cancer detection by offering radiologists complementary sensitivity, especially for low-risk lesions.
However, maintaining human readers is essential, as AI may miss aggressive subtypes like triple-negative breast cancers.
Graphical Abstract.

Related Results

Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract Introduction Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Desmoid-Type Fibromatosis of The Breast: A Case Series
Desmoid-Type Fibromatosis of The Breast: A Case Series
Abstract IntroductionDesmoid-type fibromatosis (DTF), also called aggressive fibromatosis, is a rare, benign, locally aggressive condition. Mammary DTF originates from fibroblasts ...
Abstract OI-1: OI-1 Decoding breast cancer predisposition genes
Abstract OI-1: OI-1 Decoding breast cancer predisposition genes
Abstract Women with one or more first-degree female relatives with a history of breast cancer have a two-fold increased risk of developing breast cancer. This risk i...
Spanish Breast Cancer Research Group (GEICAM)
Spanish Breast Cancer Research Group (GEICAM)
This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by Spanish Breast Cancer Research Group (GEICAM). Clinical trials...
PO-285 A review of effects of exercise on the quality of life in breast cancer survivors
PO-285 A review of effects of exercise on the quality of life in breast cancer survivors
Objective Breast cancer is one of the most common malignant tumors in women.The number of women diagnosed with breast cancer each year is also increasing.It is also the leading cau...
Effect of type lll collagen coating of electrospun scaffolds on breast cancer cell apoptosis
Effect of type lll collagen coating of electrospun scaffolds on breast cancer cell apoptosis
Breast cancer arises from the epithelial or the connective tissue components of the breast. Breast cancer is the most commonly diagnosed cancer in women, with about half a million ...
International Breast Cancer Study Group (IBCSG)
International Breast Cancer Study Group (IBCSG)
This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by International Breast Cancer Study Group (IBCSG). Clinical tria...

Back to Top